fda semaglutide warning september 2025 8, 2025: launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines FDA Declares Shortage of Novo

Patients received arGLP-1 based on availability and clinical appropriateness: semaglutide was administered via weekly subcutaneous injections, starting at 0.25 mg/week and titrated to a maximum dose of 1 mg/week, while dulaglutide was administered at a fixed dose of 1.5 mg/week

Many achieve satisfactory results at semaglutide 1.0 or 1.7 mg, or at tirzepatide 10 mg, and stay there indefinitely

Patients are also screened for infections, including Hepatitis B and C and tuberculosis, before being prescribed these medications

Wegovy is administered as a once-weekly subcutaneous injection , typically in the abdomen, thigh, or upper arm

Wait times vary by province, so requesting referrals early makes sense if you want specialist input